Foresite Capital Management V LLC cut its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,246,977 shares of the company’s stock after selling 77,094 shares during the period. Compass Therapeutics […]
Foresite Capital Management V LLC lowered its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,246,977 shares of the company’s stock after selling 77,094 shares during the quarter. […]
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 1,980,000 shares, a drop of 12.8% from the December 31st total of 2,270,000 shares. Based on an average trading volume of 511,500 shares, the short-interest ratio is currently 3.9 […]
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 in patients with advanced biliary tract cancer . Consistent with prior guidance, top.
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 2,670,000 shares, a decline of 10.1% from the November 15th total of 2,970,000 shares. Based on an average trading volume of 312,500 shares, […]